| (210) | Number of the EPO application | 21701890 |
| (220) | Filing date of the EPO application | 2021.01.08 |
| (80) | EPO patent specification publication (B) | EPB nr. 35/2024, 2024.08.28 |
| (110) | EPO patent number | 4087875 |
| (11) | Number of the document | MD 4087875 T2 |
| (21) | Number of the application | e 2022 1260 |
| (71) | Name(s) of applicant(s), code of the country | Argenx BV, BE; |
| (72) | Name(s) of inventor(s), code of the country | VERHEESEN Peter, BE;
DUPUY Patrick, BE; |
| (73) | Name(s) of owner(s), code of the country | Argenx BV, BE; |
| (54) | Title of the invention | Antagonists of human neonatal fc receptor (fcrn) for treating pemphigus disorders |
| (13) | Kind-of-document code | T2 |
| (51) | International Patent Classification | C07K 16/28 (2006.01.01); C07K 16/18 (2006.01.01); A61K 31/573 (2006.01.01); A61K 39/395 (2006.01.01); A61P 17/00 (2006.01.01); A61P 37/06 (2006.01.01) |
| (19) | Country | BE |
| (41) | Date of publication of the application | 2022.12.31 |
| (49) | Date of publication of the translation of the validated European patent specification | 2025.02.28 |
| (30) | Priority | 202062958543 P, 2020.01.08, US; 202062960647 P, 2020.01.13, US |
| (74) | Patent attorney | (Procedură) FOCŞA Valentin, bd. Renaşterii Naţionale, No. 6, of. 08, MD-2024, mun. Chişinău, Republica Moldova |
| (86) | International application | PCT/EP2021/050275, 2021.01.08 |
| (87) | International publication | WO 2021/140202, 2021.07.15 |